<DOC>
	<DOCNO>NCT02871401</DOCNO>
	<brief_summary>The investigator conduct single-center , prospective , randomize , placebo-controlled , double-blind pilot study anti-herpesvirus therapy patient idiopathic pulmonary fibrosis ( IPF ) . Patients mild , moderate severe IPF serologic evidence current past Epstein-Barr Virus ( EBV ) cytomegalovirus ( CMV ) infection . Randomization pirfenidone plus placebo pirfenidone plus valganciclovir . Thirty subject enrol randomized treatment pirfenidone plus valganciclovir ( 20 subject ) pirfenidone plus placebo ( 10 subject ) 12 week . The primary outcome safety tolerability determine type , frequency duration adverse event ( AEs ) serious adverse event ( SAEs ) 12 week study drug treatment . All study subject offer bronchoscopy bronchoalveolar lavage ( BAL ) study initiation upon completion treatment ( 12 week ) . Subjects followed routine clinic visit 6 , 9 12 month data collection .</brief_summary>
	<brief_title>A Pilot Trial Herpesvirus Treatment Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>1. age &gt; 21 &lt; 80 year 2. ability provide informed consent 3. diagnosis probable definite IPF accord American Thoracic Society ( ATS ) criteria 4. tolerance fulldose ( 2403 mg/day ) pirfenidone 5 . Positive serology EBV CMV 1 . FVC &lt; 40 % predict 2 . Diffusing capacity carbon monoxide ( DLCO ) &lt; 35 % predict ( Crapo ) 3 . Forced expiratory volume ( FEV ) 1/FVC &lt; 0.7 4 . Significant centrilobular emphysema ( &gt; 40 % HRCT ) 5 . Active tobacco use ( cigarette cigar smoking ) 6 . Resting oxygen saturation ( SpO2 ) room air &lt; 89 % 7 . Listed lung transplantation define assigned lung allocation score 8. environmental exposure ( occupational , environmental , drug , etc . ) felt principal investigator ( PI ) etiology interstitial disease 9. diagnosis collagenvascular condition ( accord publish American College Rheumatology criterion ) 10. history unstable deteriorate cardiac disease 11. acute coronary syndrome , coronary artery bypass , angioplasty within 3 month screen 12. uncontrolled arrhythmia 13. uncontrolled hypertension 14. know HIV hepatitis C 15. know cirrhosis chronic active hepatitis 16. active substance alcohol abuse 17. pregnancy lactation 18 . Women childbearing potential use medically approve mean contraception . Subjects consider childbearing potential surgically sterile postmenopausal least 2 year [ subject postmenopausal &lt; 2 year require folliclestimulating hormone ( FSH ) level assess potential become pregnant 19. clinically relevant lab abnormality ( obtain within 30 day enrollment ) , include : 1. creatinine &gt; 2 x upper limit normal ( ULN ) 2. hematology outside specify limit : white blood cell ( WBCs ) &lt; 3,500/mm3 ; hematocrit &lt; 25 % &gt; 59 % ; platelet &lt; 100,000/mm3 ; 3. total bilirubin &gt; 2 x ULN 4 . Aspartate ( AST ) alanine aminotransferase ( ALT ) / serum glutamicoxaloacetic ; transaminase ( SGOT ) , serum glutamic pyruvic transaminase ( SGPT ) &gt; 2.0 x ULN 5. alkaline phosphatase &gt; 3 x ULN 6. albumin &lt; 3.0 mg/dL screen 20. know hypersensitivity study medication 21. condition , judgment PI , might cause participation study detrimental subject PI deems make subject poor candidate 22. therapy immunosuppressant prednisone , azathioprine , mycophenolate currently anticipate need study period ( subject drug prior study require 30day washout period randomization ) 23. participation another IPF clinical treatment trial study period ( complete another IPF clinical treatment trial , 30day washout period require randomization ) 24. requirement chronic suppressive therapy valacyclovir recurrent herpes virus infection 25 . History myelodysplasia , aplastic anemia , refractory anemia , multiple myeloma .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>IPF</keyword>
	<keyword>Herpesvirus</keyword>
	<keyword>Valganciclovir</keyword>
</DOC>